Department of Radiation Oncology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (Republic of).
Strahlenther Onkol. 2023 Sep;199(9):828-837. doi: 10.1007/s00066-023-02061-1. Epub 2023 Mar 17.
We investigated the characteristics of recurrence pattern and survival of patients with non-endometrioid endometrial cancer (NEEC) and attempted to identify prognostic and treatment factors affecting disease-free survival (DFS) and overall survival (OS) of these patients.
Fifty-seven patients with histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage IA-IVA NEEC from February 2003 to December 2021 were retrospectively analyzed.
The 5‑year DFS and OS rates of the total cohort were 50.6% and 56.1%, respectively. Recurrence occurred in 28 patients (49.1%) during follow-up, and the most common recurrence pattern was distant metastasis (DM; 78.6% of total recurrences). The occurrence of relapse significantly reduced 5‑year OS (recurrence group vs. non-recurrence group: 12.5% vs. 100%; p < 0.001). In univariate analysis, adjuvant radiotherapy (RT) group showed significantly higher 5‑year DFS (56.7% vs. 37.9%; p = 0.04), local recurrence-free survival (91.6% vs. 50.5%; p = 0.01), and regional recurrence-free survival (88.2% vs. 56.5%; p < 0.01) than the non-RT group. In multivariate analysis, advanced FIGO stage was identified as a negative prognostic factor for DFS and OS. Lymphovascular space invasion (LVSI) and adjuvant RT were independent prognostic factors for DFS.
The most common recurrence pattern observed in patients with NEEC was DM. FIGO stage and LVSI were identified as prognostic factors for survival, and RT was identified as a therapeutic modality that could increase DFS. To improve the OS of patients with NEEC, the addition of effective chemotherapy that can reduce DM may be important.
我们研究了非子宫内膜样癌(NEEC)患者的复发模式和生存特点,并试图确定影响这些患者无病生存(DFS)和总生存(OS)的预后和治疗因素。
回顾性分析 2003 年 2 月至 2021 年 12 月期间 57 例经组织学证实为国际妇产科联合会(FIGO)分期 IA-IVA 期的 NEEC 患者。
总队列的 5 年 DFS 和 OS 率分别为 50.6%和 56.1%。随访期间 28 例(49.1%)患者复发,最常见的复发模式为远处转移(DM;总复发的 78.6%)。复发显著降低了 5 年 OS(复发组 vs. 非复发组:12.5% vs. 100%;p<0.001)。单因素分析显示,辅助放疗(RT)组 5 年 DFS(56.7% vs. 37.9%;p=0.04)、局部无复发生存(91.6% vs. 50.5%;p=0.01)和区域无复发生存(88.2% vs. 56.5%;p<0.01)显著高于非 RT 组。多因素分析显示,FIGO 分期较晚是 DFS 和 OS 的不良预后因素。淋巴血管间隙浸润(LVSI)和辅助 RT 是 DFS 的独立预后因素。
NEEC 患者最常见的复发模式是 DM。FIGO 分期和 LVSI 是生存的预后因素,RT 是增加 DFS 的治疗方式。为了提高 NEEC 患者的 OS,加入可以降低 DM 的有效化疗可能很重要。